Erythrocin (Erythromycin Lactobionate) Patent Expiration, LOE Window & CMS Spending
Erythrocin (Erythromycin Lactobionate) by Pfizer: FDA Approved Brand (No Listed Patent), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N050609 (NDA) |
| Exclusivity / Cliff Horizon | FDA Approved Brand (No Listed Patent) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 117.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.